Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.78 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.78 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.78 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.78 |
| ▸ | ST14 | Q9Y5Y6 | 6/20 | 0.78 |
| ▸ | PLG | P00747 | 4/20 | 0.78 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852204 | 1.00 | F2 (0.78) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL9880184 | 0.87 | ST14 (1.00) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL852017 | 0.87 | ST14 (1.00) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL8509813 | 0.83 | ST14 (0.55) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL851347 | 0.83 | ST14 (0.55) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL8512644 | 0.83 | ST14 (0.55) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL8513660 | 0.83 | F2 (0.72) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL851605 | 0.83 | F2 (0.72) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL851231 | 0.81 | F2 (0.62) | F2PRSS1PRSS2PRSS3ST14 | |
| SCHEMBL851181 | 0.79 | PRSS1 (0.69) | F2PRSS1PRSS2PRSS3ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | F2 112/4885PRSS1 3/4885PRSS2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.